Trial Profile
A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Naporafenib (Primary) ; Ribociclib (Primary) ; Rineterkib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Skin cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 15 Apr 2024 Planned End Date changed from 5 Apr 2024 to 1 May 2024.
- 15 Apr 2024 Planned primary completion date changed from 5 Apr 2024 to 1 May 2024.
- 09 Nov 2023 Planned End Date changed from 26 Apr 2024 to 5 Apr 2024.